Prevalence of Undiagnosed and Undertreated Peripheral Vascular Disease in Women Calls for Increased Research Efforts

Peripheral vascular disease (PVD) is a condition that can profoundly impact a person’s health, yet it remains under-recognized and understudied, particularly in women. This complex disorder affects not only arteries and veins but also the lymphatic systems throughout the body. Understanding how PVD manifests differently in men and women is crucial to ensuring appropriate diagnosis, treatment, and care. Recent scientific advancements and recommendations from the American Heart Association shed light on the significant disparities that exist between the sexes in terms of incidence, risk factors, symptoms, and outcomes related to PVD.

Research indicates that while both men and women experience PVD, there are critical differences in how this disease presents itself in women. Women often exhibit more subtle or atypical symptoms, which frequently leads to delays in diagnosis or underdiagnosis altogether. For instance, in conditions such as Peripheral Artery Disease (PAD), which is the most prevalent type of PVD affecting blood flow to the limbs, men and women statistically experience similar rates. However, the manifestation of this condition tends to be less pronounced in women, who may complain of fewer and less recognizable symptoms, thereby complicating timely intervention.

The nuances of these symptoms in women not only result in increased functional limitations—such as reduced walking speeds and shorter distances—but also contribute to an alarming trend: women are less likely than men to receive treatment that aligns with established clinical guidelines. This disparity is particularly striking among women of color; studies reveal that Black women have a much higher lifetime risk of developing PAD compared to their white counterparts, yet they are often underserved when it comes to evidence-based treatments.

Research on aortic diseases presents a similarly troubling picture. Women diagnosed with aortic disease tend to enter treatment later in life and often exhibit more severe disease manifestations. Although estrogen may offer a protective factor against certain aortic conditions, women face a disproportionately higher risk of life-threatening complications such as aneurysm rupture. Alarmingly, women are three times more likely than men to suffer ruptured aneurysms at comparable sizes, underscoring a critical need for enhanced awareness and targeted screening.

The different types of PVD display various gender-based discrepancies that should not be ignored. For instance, fibromuscular dysplasia—a condition characterized by abnormal growth in the cells of a blood vessel—occurs between five and nine times more frequently in women than in men. Conversely, specific artery disorders like popliteal artery aneurysms are significantly more prevalent in men, involved in vascular intricacies that highlight the variety of presentations of PVD.

Carotid artery disease and its associations with stroke risk also showcase differences between men and women. While women generally present with smaller arterial plaque compared to men, the nature of that plaque can affect stroke risk differently for each sex. Women may experience unique risk factors, such as having dealt with preeclampsia during pregnancy or entering menopause later in life, impacting their vascular health significantly.

The unique challenges faced by women in terms of renal and mesenteric artery disease exemplify the pressing need for focused research. Evidence suggests that chronic mesenteric ischemia—a condition involving reduced blood flow to the intestines—is three times more likely to occur in women than in men. Meanwhile, emerging data indicate that Black adults facing renal artery stenosis have a heightened prevalence of severe hypertension, further complicating treatment considerations.

The writing group behind this scientific statement emphasizes the necessity for future research that includes rigorous analysis of sex-specific differences in treatments and outcomes. One of the urgent requirements is ensuring women are adequately represented in clinical trials to yield a comprehensive understanding of treatment responses. A balanced representation can yield vital insights into how various therapies could be optimized for women, who often exhibit different disease trajectories compared to men.

Healthcare professionals must also be educated about the significance of recognizing these disparities. Enhanced training to identify female-specific symptoms and risks associated with PVD can lead to improved diagnostic accuracy and more effective management. Additionally, refining current screening strategies to account for sex-specific risk factors can ensure that women are not inadvertently overlooked during routine assessments.

Access to guideline-recommended therapies remains another critical concern for women grappling with PVD. Addressing barriers related to healthcare delivery that prevent women from receiving timely and effective treatment is essential for closing the gap in outcomes. Equitable healthcare practices are fundamental in addressing these disparities, ultimately leading to double-sided benefits: enhancing women’s health and promoting wider societal benefits.

In conclusion, the scientific community is called upon to amplify research efforts focused on PVD, bringing to light the pressing need for tailored prevention, screening, and treatment strategies for women. As researchers and clinicians work together to develop a comprehensive understanding of how PVD uniquely impacts women, the hope is to forge pathways that lead to equitable health outcomes. As we propel forward, there is a collective responsibility to ensure that women’s cardiovascular health is prioritized, paving the way for innovative solutions that will drastically improve the quality of life and longevity for those affected by this often-overlooked disease.